10-Q Filing

BEONE MEDICINES LTD. CIK: 1651308 Q2 2020

Filing Information

Form Type	10-Q
Accession Number	`0001651308-20-000117`
Period End Date	20200630
Filing Date	20200806
Fiscal Year	2020
Fiscal Period	Q2
XBRL Instance	bgne-20200630_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 93 Income Statement 74 Cash Flow Statement 101 Stockholders Equity 37 Comprehensive Income 26

Balance Sheet 93 line items

Line Item	Tag	Value	Unit	Period
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Ordinary shares, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$918.95M	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Ordinary shares, shares authorized (in shares)	`CommonStockSharesAuthorized`	9.50B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.35B	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$283.00K	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	801.34M	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$14.57M	USD	Point-in-time
Ordinary shares, shares issued (in shares)	`CommonStockSharesIssued`	1.01B	shares	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	1.01B	shares	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$1.81B	USD	Point-in-time
Short-term investments	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$364.73M	USD	Point-in-time
Ordinary shares, shares outstanding (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$70.88M	USD	Point-in-time
Accounts receivable, net	`AccountsReceivableNetCurrent`	$61.66M	USD	Point-in-time
Inventories	`InventoryNet`	$33.23M	USD	Point-in-time
Inventories	`InventoryNet`	$28.55M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$144.47M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$90.24M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$1.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.39B	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$4.60M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$9.16M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$258.11M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$242.40M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$90.62M	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$82.52M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.38M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$5.85M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$39.80M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$37.89M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$112.38M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$68.45M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$510.89M	USD	Point-in-time
Total non-current assets	`AssetsNoncurrent`	$439.59M	USD	Point-in-time
Total assets	`Assets`	$3.90B	USD	Point-in-time
Total assets	`Assets`	$1.61B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$122.49M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$157.17M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$207.92M	USD	Point-in-time
Accrued expenses and other payables	`AccruedLiabilitiesCurrent`	$163.56M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$13.45M	USD	Point-in-time
Tax payable	`TaxesPayableCurrent`	$10.45M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$10.81M	USD	Point-in-time
Operating lease liabilities, current portion	`OperatingLeaseLiabilityCurrent`	$12.89M	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	-	USD	Point-in-time
Research and development cost share liability, current portion	`ResearchAndDevelopmentCostShareLiabilityCurrentPortion`	$136.70M	USD	Point-in-time
Short-term bank loans	`LongTermDebtCurrent`	-	USD	Point-in-time
Short-term bank loans	`LongTermDebtCurrent`	$26.06M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$310.31M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$551.20M	USD	Point-in-time
Long-term bank loan	`LongTermDebtNoncurrent`	$131.49M	USD	Point-in-time
Long-term bank loan	`LongTermDebtNoncurrent`	$83.31M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$157.38M	USD	Point-in-time
Shareholder loan	`DueToRelatedPartiesNoncurrent`	$160.16M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$25.83M	USD	Point-in-time
Operating lease liabilities, non-current portion	`OperatingLeaseLiabilityNoncurrent`	$31.16M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$11.38M	USD	Point-in-time
Deferred tax liabilities	`DeferredIncomeTaxLiabilitiesNet`	$10.53M	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	-	USD	Point-in-time
Research and development cost share liability, non-current portion	`ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion`	$424.89M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$46.56M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$46.51M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$805.60M	USD	Point-in-time
Total non-current liabilities	`LiabilitiesNoncurrent`	$323.62M	USD	Point-in-time
Total liabilities	`Liabilities`	$633.93M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.36B	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,014,976,692 and 801,340,698 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$102.00K	USD	Point-in-time
Ordinary shares, US$0.0001 par value per share; 9,500,000,000 shares authorized; 1,014,976,692 and 801,340,698 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively	`CommonStockValue`	$79.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$2.93B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$5.20B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-8.00M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-9.30M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-2.65B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.96B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$2.54B	USD	Point-in-time
Total BeiGene, Ltd. shareholders equity	`StockholdersEquity`	$962.21M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$10.19M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$16.15M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.57B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.55B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.62B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$1.61B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$3.90B	USD	Point-in-time

Income Statement 74 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$117.69M	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$321.18M	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$243.35M	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$65.64M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$17.84M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$28.46M	USD	2 Qtrs
Cost of sales - product	`CostOfGoodsAndServicesSold`	$14.31M	USD	1 Quarter
Cost of sales - product	`CostOfGoodsAndServicesSold`	$33.10M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$590.27M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$228.76M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$285.97M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$407.11M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$231.13M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$139.89M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$82.25M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$124.05M	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$188.00K	USD	1 Quarter
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$471.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$663.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$332.00K	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$424.51M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$329.18M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$580.77M	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$850.33M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-259.59M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-85.83M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-732.63M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-358.88M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$2.89M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$7.80M	USD	2 Qtrs
Interest income, net	`InterestIncomeExpenseNet`	$1.11M	USD	1 Quarter
Interest income, net	`InterestIncomeExpenseNet`	$7.36M	USD	2 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$23.66M	USD	2 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$-878.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$19.98M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$850.00K	USD	2 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-701.18M	USD	2 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-251.38M	USD	2 Qtrs
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-337.79M	USD	1 Quarter
Loss before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-83.83M	USD	1 Quarter
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$2.13M	USD	1 Quarter
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$2.65M	USD	2 Qtrs
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$79.00K	USD	2 Qtrs
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-1.48M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-701.26M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-254.02M	USD	2 Qtrs
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-813.00K	USD	2 Qtrs
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-2.32M	USD	2 Qtrs
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-1.12M	USD	1 Quarter
Less: net loss attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-384.00K	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-253.21M	USD	2 Qtrs
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-85.57M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-335.20M	USD	1 Quarter
Net loss attributable to BeiGene, Ltd.	`NetIncomeLoss`	$-698.94M	USD	2 Qtrs
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.33	USD	2 Qtrs
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.69	USD	2 Qtrs
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.11	USD	1 Quarter
Net loss per share attributable to BeiGene, Ltd., basic and diluted (in dollars per share)	`EarningsPerShareBasicAndDiluted`	$-0.33	USD	1 Quarter
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	776.14M	shares	2 Qtrs
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	1.01B	shares	1 Quarter
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	777.51M	shares	1 Quarter
Weighted-average shares outstanding, basic and diluted (in shares)	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	1.01B	shares	2 Qtrs
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-9.01	USD	2 Qtrs
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-1.43	USD	1 Quarter
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-4.24	USD	2 Qtrs
Net loss per American Depositary Share (ADS), basic and diluted (in dollars per share)	`EarningsPerAmericanDepositoryShare`	$-4.31	USD	1 Quarter
Weighted-average ADSs outstanding, basic and diluted (shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	77.71M	shares	1 Quarter
Weighted-average ADSs outstanding, basic and diluted (shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	77.54M	shares	2 Qtrs
Weighted-average ADSs outstanding, basic and diluted (shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	59.70M	shares	2 Qtrs
Weighted-average ADSs outstanding, basic and diluted (shares)	`WeightedAverageNumberOfAmericanDepositorySharesOutstanding`	59.81M	shares	1 Quarter

Cash Flow Statement 101 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-701.26M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-254.02M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$15.62M	USD	2 Qtrs
Depreciation and amortization expense	`DepreciationDepletionAndAmortization`	$7.11M	USD	2 Qtrs
Share-based compensation expenses	`ShareBasedCompensation`	$83.72M	USD	2 Qtrs
Share-based compensation expenses	`ShareBasedCompensation`	$58.99M	USD	2 Qtrs
Unrealized gains on equity method investments	`UnrealizedGainLossOnInvestments`	$11.26M	USD	2 Qtrs
Unrealized gains on equity method investments	`UnrealizedGainLossOnInvestments`	-	USD	2 Qtrs
Gain on deconsolidation of entity	`DeconsolidationGainOrLossAmount`	$11.31M	USD	2 Qtrs
Gain on deconsolidation of entity	`DeconsolidationGainOrLossAmount`	-	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$43.00M	USD	2 Qtrs
Acquired in-process research and development	`AcquiredInProcessResearchAndDevelopment`	$49.00M	USD	2 Qtrs
Amortization of research and development cost share liability	`AmortizationofResearchAndDevelopmentFinancingLiability`	-	USD	2 Qtrs
Amortization of research and development cost share liability	`AmortizationofResearchAndDevelopmentFinancingLiability`	$-55.24M	USD	2 Qtrs
Non-cash interest expense	`InterestExpenseOperatingActivities`	$5.11M	USD	2 Qtrs
Non-cash interest expense	`InterestExpenseOperatingActivities`	$3.76M	USD	2 Qtrs
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-1.06M	USD	2 Qtrs
Deferred income tax benefits	`DeferredIncomeTaxesAndTaxCredits`	$-1.46M	USD	2 Qtrs
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-5.46M	USD	2 Qtrs
Other items, net	`OtherOperatingActivitiesCashFlowStatement`	$-863.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$17.05M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-9.09M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$4.68M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$32.81M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$5.92M	USD	2 Qtrs
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$54.59M	USD	2 Qtrs
Operating lease right-of-use assets	`IncreaseDecreaseInOperatingLeaseRightofUseAsset`	$3.60M	USD	2 Qtrs
Operating lease right-of-use assets	`IncreaseDecreaseInOperatingLeaseRightofUseAsset`	$7.46M	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$10.29M	USD	2 Qtrs
Other non-current assets	`IncreaseDecreaseInOtherNoncurrentAssets`	$-2.63M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$34.85M	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$21.43M	USD	2 Qtrs
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$3.54M	USD	2 Qtrs
Accrued expenses and other payables	`IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities`	$44.47M	USD	2 Qtrs
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-3.01M	USD	2 Qtrs
Tax payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-3.71M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-27.98M	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	-	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$383.00K	USD	2 Qtrs
Operating lease liabilities	`IncreaseDecreaseInOtherNoncurrentLiabilities`	$7.41M	USD	2 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$-49.00K	USD	2 Qtrs
Other long-term liabilities	`IncreaseDecreaseInOperatingLeaseLiability`	$21.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-604.89M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-218.08M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$54.14M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$43.27M	USD	2 Qtrs
Deconsolidation of entity	`CashDivestedFromDeconsolidation`	$2.02M	USD	2 Qtrs
Deconsolidation of entity	`CashDivestedFromDeconsolidation`	-	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$2.44B	USD	2 Qtrs
Purchases of investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$710.79M	USD	2 Qtrs
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$997.24M	USD	2 Qtrs
Proceeds from sale or maturity of investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$1.17B	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$49.00M	USD	2 Qtrs
Purchase of in-process research and development	`PaymentsToPurchaseInProcessResearchAndDevelopment`	$43.00M	USD	2 Qtrs
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.54B	USD	2 Qtrs
Net cash (used in) provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$364.43M	USD	2 Qtrs
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStockNetOfUnderwriterDiscount`	$2.16B	USD	2 Qtrs
Proceeds from sale of ordinary shares, net of cost	`ProceedsFromIssuanceOfCommonStockNetOfUnderwriterDiscount`	-	USD	2 Qtrs
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	$616.83M	USD	2 Qtrs
Proceeds from research and development cost share liability	`ProceedsFromResearchAndDevelopmentFinancingLiability`	-	USD	2 Qtrs
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	-	USD	2 Qtrs
Capital contribution from noncontrolling interest	`ProceedsFromMinorityShareholders`	$4.00M	USD	2 Qtrs
Proceeds from long-term bank loan	`ProceedsFromLongTermLinesOfCredit`	$49.52M	USD	2 Qtrs
Proceeds from long-term bank loan	`ProceedsFromLongTermLinesOfCredit`	$43.70M	USD	2 Qtrs
Proceeds from short-term bank loan	`ProceedsFromShortTermDebt`	$26.20M	USD	2 Qtrs
Proceeds from short-term bank loan	`ProceedsFromShortTermDebt`	-	USD	2 Qtrs
Proceeds from option exercises and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$10.64M	USD	2 Qtrs
Proceeds from option exercises and employee share purchase plan	`ProceedsFromStockOptionsExercised`	$28.20M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.88B	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$58.35M	USD	2 Qtrs
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-4.29M	USD	2 Qtrs
Effect of foreign exchange rate changes, net	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-2.73M	USD	2 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$729.12M	USD	2 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$201.96M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.35B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$942.68M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.35B	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$620.77M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$942.68M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$740.71M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$918.95M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$618.01M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.35B	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$283.00K	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$14.57M	USD	Point-in-time
Short-term restricted cash	`RestrictedCashAndCashEquivalentsAtCarryingValue`	$288.00K	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$2.48M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$4.60M	USD	Point-in-time
Long-term restricted cash	`RestrictedCashAndCashEquivalentsNoncurrent`	$9.16M	USD	Point-in-time
Income taxes paid	`IncomeTaxesPaidNet`	$9.25M	USD	2 Qtrs
Income taxes paid	`IncomeTaxesPaidNet`	$7.87M	USD	2 Qtrs
Interest paid	`InterestPaidNet`	$2.09M	USD	2 Qtrs
Interest paid	`InterestPaidNet`	$3.35M	USD	2 Qtrs
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$35.93M	USD	2 Qtrs
Acquisitions of equipment included in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$28.96M	USD	2 Qtrs

Stockholders Equity 37 line items

Line Item	Tag	Value	Unit	Period
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.57B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.55B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.62B	USD	Point-in-time
Balance at the beginning of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	1.01B	shares	Point-in-time
Balance at the beginning of period (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Issuance of ordinary shares in connection with collaboration	`StockIssuedDuringPeriodValueNewIssues`	$2.16B	USD	1 Quarter
Contributions from shareholders	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	$4.00M	USD	1 Quarter
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$6.27M	USD	1 Quarter
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$4.37M	USD	1 Quarter
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$16.57M	USD	1 Quarter
Exercise of options, ESPP and release of Restricted Share Units (RSUs)	`StockIssuedDuringPeriodValueStockOptionsExercised`	$11.63M	USD	1 Quarter
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$45.47M	USD	1 Quarter
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$26.39M	USD	1 Quarter
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$32.60M	USD	1 Quarter
Share-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$38.26M	USD	1 Quarter
Deconsolidation of entity	`NoncontrollingInterestDecreaseFromDeconsolidation`	$3.54M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$4.44M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-2.74M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-6.44M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$1.35M	USD	1 Quarter
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-701.26M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-254.02M	USD	2 Qtrs
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	1.01B	shares	Point-in-time
Balance at the ending of period (in shares)	`CommonStockSharesOutstanding`	801.34M	shares	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.75B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.57B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.83B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$2.55B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.62B	USD	Point-in-time
Balance at the end of period	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$978.36M	USD	Point-in-time

Comprehensive Income 26 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-168.07M	USD	1 Quarter
Net loss	`ProfitLoss`	$-85.95M	USD	1 Quarter
Net loss	`ProfitLoss`	$-336.32M	USD	1 Quarter
Net loss	`ProfitLoss`	$-701.26M	USD	2 Qtrs
Net loss	`ProfitLoss`	$-364.94M	USD	1 Quarter
Net loss	`ProfitLoss`	$-254.02M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-3.58M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.73M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-2.62M	USD	2 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-7.34M	USD	1 Quarter
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$901.00K	USD	1 Quarter
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.59M	USD	2 Qtrs
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.23M	USD	2 Qtrs
Unrealized holding gain, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-4.47M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-702.65M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-256.02M	USD	2 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-92.39M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-339.06M	USD	1 Quarter
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-1.06M	USD	2 Qtrs
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-2.41M	USD	2 Qtrs
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-523.00K	USD	1 Quarter
Less: comprehensive loss attributable to noncontrolling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-1.10M	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-91.87M	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-254.96M	USD	2 Qtrs
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-337.95M	USD	1 Quarter
Comprehensive loss attributable to BeiGene, Ltd.	`ComprehensiveIncomeNetOfTax`	$-700.24M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.